Singapore markets closed
  • Straits Times Index

    3,153.14
    -4.83 (-0.15%)
     
  • S&P 500

    4,238.35
    -9.09 (-0.21%)
     
  • Dow

    34,312.66
    -166.94 (-0.48%)
     
  • Nasdaq

    14,089.24
    +19.82 (+0.14%)
     
  • BTC-USD

    40,829.11
    +4,944.24 (+13.78%)
     
  • CMC Crypto 200

    1,014.36
    +45.52 (+4.70%)
     
  • FTSE 100

    7,161.51
    +27.45 (+0.38%)
     
  • Gold

    1,869.10
    -10.50 (-0.56%)
     
  • Crude Oil

    71.56
    +0.65 (+0.92%)
     
  • 10-Yr Bond

    1.4840
    +0.0220 (+1.50%)
     
  • Nikkei

    29,161.80
    +213.07 (+0.74%)
     
  • Hang Seng

    28,842.13
    +103.23 (+0.36%)
     
  • FTSE Bursa Malaysia

    1,582.46
    +7.30 (+0.46%)
     
  • Jakarta Composite Index

    6,080.38
    -15.11 (-0.25%)
     
  • PSE Index

    6,917.49
    +9.70 (+0.14%)
     

United States Axial Spondyloarthritis (axSpA) Market Insight, Epidemiology and Market Forecast Report 2021-2030 - ResearchAndMarkets.com

·5-min read

The "Axial Spondyloarthritis (axSpA) - United States Market Insight, Epidemiology and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.

This 'Axial Spondyloarthritis (axSpA)-Market Insights, Epidemiology, and Market Forecast-2030' report deliver an in-depth understanding of the axSpA, historical, and forecasted epidemiology as well as the axSpA market trends in the United States

The axSpA market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted United States axSpA market size from 2018 to 2030.

The Report also covers current axSpA treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, and market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Key Findings

  • The market size of Axial Spondyloarthritis (axSpA) in the US is expected to increase in 2030 from USD 4,716 million in 2020, at a CAGR of 9.8% for the study period 2018-2030.

  • According to analysis, the current treatment market includes conventional therapies, biologics, and Cox Inhibitors.

  • The market size generated by Cox Inhibitors in 2020 was estimated to be USD 177 million, which by 2030 is expected to increase. Among all the US potential therapies, the highest market is expected to be captured by Bimekizumab.

Market Insights:

  • What was the axSpA market share (%) distribution in 2018 and how it would look like in 2030?

  • What would be the axSpA total market size as well as market size by therapies across the Unites States during the forecast period (2021-2030)?

  • What are the key findings pertaining to the market across the United States and which country will have the largest axSpA market size during the forecast period (2021-2030)?

  • At what CAGR, the axSpA market is expected to grow at the United States level during the forecast period (2021-2030)?

  • What would be the axSpA market outlook across the United States during the forecast period (2021-2030)?

  • What would be the axSpA market growth till 2030 and what will be the resultant market size in the year 2030?

  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Key Topics Covered:

1 Key Insights

2 Report Introduction

3 Executive Summary of Axial Spondyloarthritis (axSpA)

4 Disease Background and Overview

4.1 Introduction

4.2 Cause

4.3 Etiology

4.3.1 Endogenous Factors

4.3.2 Exogenous Factors

4.4 Risk Factors

4.4.1 Gender

4.4.2 Family History

4.4.3 Genetic Predisposition

4.4.4 Age

4.5 Signs and symptoms

4.6 Genetics - an insight into the pathogenesis

4.6.1 HLAB27 causing AS

4.6.2 Antigen processing and presentation

4.6.3 IL-17 and type 3 immunity in AS

4.6.4 IL-17

4.6.5 IL-23 signaling

4.6.6 Targeting type-3 immunity in AS

4.7 Biomarkers

4.7.1 Genetic biomarkers

4.7.2 Markers for inflammation

4.7.3 Cartilage Turnover Markers

4.7.4 Other Biomarkers

4.8 Clinical Manifestations

4.8.1 Peripheral arthritis

4.8.2 Enthesitis

4.8.3 Restriction of spinal mobility

4.8.4 Hip and shoulder joints

4.8.5 Dactylitis

4.8.6 Extra-articular locations

4.9 Diagnosis

4.9.1 Blood tests

4.9.2 Imaging tests

4.1 Differential Diagnosis

4.11 Underdiagnoses and Diagnostic Delay

4.12 Diagnostic Criteria

4.13 New York Classification Criteria: Diagnostic Criteria for AS

5 Treatment and Management

5.1 Therapeutic treatment

5.1.1 Therapy

5.1.2 Surgery

5.1.3 Lifestyle and home remedies

5.2 Treatment Guidelines

5.2.1 ASAS-EULAR management recommendations for axial spondyloarthritis

5.2.2 Recommendations for the treatment of axial spondyloarthritis

5.2.3 APLAR axial spondyloarthritis treatment recommendations

6 Epidemiology and Patient Population

6.1 Methodology

6.2 United States

6.2.1 Assumptions and Rationale

6.2.2 Total Prevalent Cases of Axial Spondyloarthritis in the United States

6.2.3 Total Diagnosed Prevalent Cases of Axial Spondyloarthritis in the United States

6.2.4 Gender-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis in the United States

6.2.5 Age-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis in the United States

6.2.6 Gene-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis in the United States

7 Organizations contributing towards Axial Spondyloarthritis (AxSpA)

8 Patient Journey

9 Case Reports

10 Marketed Products

10.1 Key-cross Competition

10.2 Cimzia (Certolizumab pegol): UCB

10.3 Humira (adalimumab): AbbVie

10.4 Celebrex (celecoxib): Pfizer

10.5 Enbrel (Etanercept): Amgen/Pfizer

10.6 Remicade (Infliximab): Janssen Biotech

10.7 Simponi (Golimumab): Janssen Biotech

10.8 Vimovo (naproxen and esomeprazole magnesium): Pozen

10.9 Cosentyx: Novartis

10.10 Indocin: Iroko Pharmaceuticals

10.11 Naprelan: Syntex Pharmaceuticals

10.12 Rayos (Prednisone): Horizon Pharma

10.13 Taltz (ixekizumab): Eli Lilly and Company

11 Emerging Therapies

11.1 Key Cross Competition

11.2 Tofacitinib: Pfizer

11.3 Bimekizumab: UCB Biopharma

11.4 Ilumya (Tildrakizumab): Sun Pharma Global

11.5 Namilumab: Izana Bioscience

11.6 ILT-101(Interleukin 2): Iltoo Pharma

11.7 Brodalumab (KHK4827): Kyowa Kirin

11.8 Rinvoq (Upadacitinib): AbbVie

11.9 Filgotinib: Galapagos/Gilead

12 Axial Spondyloarthritis (AxSpA): Market Analysis

12.1 Market Methodology

12.2 Attribute Analysis

12.3 Potential of Emerging Therapies and Current therapies

12.4 Key Market Forecast Assumptions

13 United States Market Outlook

13.1 United States Market Size

13.1.1 Total Market Size of Axial Spondyloarthritis in United States

13.1.2 Market Size of Axial Spondyloarthritis by Therapies in United States

14 Unmet Needs

15 Market Drivers

16 Market Barriers

17 SWOT Analysis

18 KOL Views

19 Access and Reimbursement Overview: Axial Spondyloarthritis (AxSpA)

20 Appendix

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/5h6l2k

View source version on businesswire.com: https://www.businesswire.com/news/home/20210513005571/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900